Novartis targets Xolair successor in buyout of startup Excellergy
BioPharma Dive
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche s popular medicine.
pharminent
March 27, 2026 (Last updated: March 30, 2026)
BioPharma Dive
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche s popular medicine.